Cargando…

Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data

INTRODUCTION: The frequency of neutropenia associated with lung cancer chemotherapy outside of randomized trials is largely unknown because administrative coding underestimates its prevalence. This study compared International Classification of Diseases (ICD) diagnosis codes and electronic laborator...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knerr, Sarah, Hu, Elaine Y., Zeliadt, Steven B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AcademyHealth 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389434/ https://www.ncbi.nlm.nih.gov/pubmed/28459084 http://dx.doi.org/10.13063/2327-9214.1269

Ejemplares similares

Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy
por: do Nascimento, Talita Garcia, et al.
Publicado: (2014)

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
por: Weycker, Derek, et al.
Publicado: (2015)

Coronavirus disease 2019 in veterans receiving care at veterans health administration facilities
por: Luo, Jessica, et al.
Publicado: (2021)

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012)

Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration
por: Sy, S. Kenneth, et al.
Publicado: (2016)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
por: Schwartzberg, Lee S, et al.
Publicado: (2018)

COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim
por: Gwak, Hongki, et al.
Publicado: (2022)

Indicators of Elder Mistreatment: Correlates among Veterans Receiving Care in the Veterans Health Administration
por: Jedele, Jenefer, et al.
Publicado: (2021)

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
por: del Giglio, A, et al.
Publicado: (2008)

Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy
por: Suthepwanon, Apisada, et al.
Publicado: (2022)

Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy
por: Kim, Chang Gon, et al.
Publicado: (2016)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
por: Otremba, Burkhard, et al.
Publicado: (2018)

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
por: Hashiguchi, Yasunori, et al.
Publicado: (2015)

Incidence of febrile neutropenia with commonly used chemotherapy regimen in localized breast cancer
por: Palukuri, Nageswara Reddy, et al.
Publicado: (2020)

Pro-inflammatory cytokine ratios determine the clinical course of febrile neutropenia in children receiving chemotherapy
por: Siegmund, Mira, et al.
Publicado: (2020)

The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
por: Li, Edward, et al.
Publicado: (2021)

Incidence and Impact of Baseline Electrolyte Abnormalities in Patients Admitted with Chemotherapy Induced Febrile Neutropenia
por: Shaikh, Asim Jamal, et al.
Publicado: (2011)

Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level
por: Baig, Hassam, et al.
Publicado: (2018)

Chemotherapy administration checklist for patients receiving chemotherapy: Development and validation
por: Miglani, Gitika, et al.
Publicado: (2022)

“There’s a huge benefit just to know that someone cares:” a qualitative examination of rural veterans’ experiences with TelePain
por: Silvestrini, Molly, et al.
Publicado: (2021)

Management of chemotherapy-associated febrile neutropenia
por: Cameron, D
Publicado: (2009)

Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia
por: Nakamura, Fumihiko, et al.
Publicado: (2019)

Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
por: Boccia, Ralph, et al.
Publicado: (2022)

Preoperative Nutritional Status Contributes to the Development of Neutropenia Event in Patients With Gastric Cancer Receiving CAPEOX Adjuvant Chemotherapy
por: Xiao, Ai Tang, et al.
Publicado: (2020)

Colorectal cancer adjuvant chemotherapy trends among a nonelderly veteran cohort at a southern veterans health administration
por: Martin, Richard L., et al.
Publicado: (2021)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
por: Hoggatt, Jonathan, et al.
Publicado: (2015)

Properdin Levels in Individuals with Chemotherapy-Induced Neutropenia
por: Tsyrkunou, Artsiom, et al.
Publicado: (2016)

Digital Health Skillsets and Digital Preparedness: Comparison of Veterans Health Administration Users and Other Veterans Nationally
por: Wray, Charlie, et al.
Publicado: (2022)

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review
por: Fernandes, Ricardo, et al.
Publicado: (2017)

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients
por: Kukec, Renata Rezonja, et al.
Publicado: (2015)

Isolated Neutropenia/Benign Ethnic Neutropenia: A Common Clinical and Laboratory Finding in Southern and Western Saudi Arabia
por: Awan, Zuhier A, et al.
Publicado: (2021)

Difference in Neutropenia due to Administration Schedule of TAS-102
por: Yoshida, Yoichiro, et al.
Publicado: (2017)

Transgender Veterans and the Veterans Health Administration: Exploring the Experiences of Transgender Veterans in the Veterans Affairs Healthcare System
por: Rosentel, Kris, et al.
Publicado: (2016)

A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis
por: Mahtani, Reshma L., et al.
Publicado: (2022)

A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices
por: Rifkin, Robert M., et al.
Publicado: (2022)

Chemotherapy induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria
por: Salako, Omolola, et al.
Publicado: (2021)

Infertility Services for Veterans Enrolled in Veterans Health Administration Care
por: Kroll-Desrosiers, Aimee, et al.
Publicado: (2023)

How Asian Breast Cancer Patients Experience Unequal Incidence of Chemotherapy Side Effects: A Look at Ethnic Disparities in Febrile Neutropenia Rates
por: Lim, Zi Lin, et al.
Publicado: (2023)

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
por: Vakkalanka, Bhanu, et al.
Publicado: (2011)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0vvc0h64e1e0msocgsub652cv7